Video content above is prompted by the following:
- Provide a brief overview of the current guidelines for the treatment of metastatic uveal melanoma.
- How has the approval of tebentafusp impacted the treatment landscape?
- How do you determine the right treatment for each patient?
- Provide a brief overview of the mechanism of action of tebentafusp. Which patients are eligible for this treatment?
- Why is it important for patients to know if they are HLA-A*02:01 positive?
- For patients not eligible for tebentafusp, what are your recommendations?
- As an advocate, how would you advise patients on how to approach selecting the best treatment option?
- What factors impact patients’ treatment selection, and what barriers do they face when selecting a treatment?
- How do you encourage patients to advocate for themselves when making decisions for their treatment?
- General query for these questions: Should they say the patient would work with their doctor to select best treatment for their situation?